Dr. Peter A. Kaufman
Claim this profileThe University of Vermont Medical Center Inc.
Studies Breast Cancer
Studies Cancer
8 reported clinical trials
18 drugs studied
Area of expertise
1Breast Cancer
Stage IV
ER positive
HER2 negative
2Cancer
Stage IV
Stage III
HER2 negative
Affiliated Hospitals
Clinical Trials Peter A. Kaufman is currently running
Lasofoxifene and Abemaciclib vs Fulvestrant and Abemaciclib
for Breast Cancer
The goal of this clinical trial is to assess the efficacy, safety and tolerability of the combination of lasofoxifene and abemaciclib compared to fulvestrant and abemaciclib for the treatment of pre- and postmenopausal women and men who have previously received ribociclib or palbociclib-based treatment and have locally advanced or metastatic estrogen receptor positive (ER+)/human epidermal growth factor 2 negative (HER2-) breast cancer with an estrogen receptor 1 (ESR1) mutation. The main question the study aims to answer is: • To compare the efficacy of the combination of lasofoxifene and abemaciclib with that of fulvestrant and abemaciclib Participants will receive either receive 5 mg/d of oral lasofoxifene plus oral abemaciclib 150 mg twice a day or the combination of fulvestrant 500 mg intramuscular (IM) on Days 1, 15, and 29 and then once monthly thereafter plus oral abemaciclib 150 mg twice a day.
Recruiting2 awards Phase 312 criteria
Imlunestrant + Abemaciclib
for Breast Cancer
This trial is testing a new drug called imlunestrant, alone and in combination with another drug, abemaciclib, for patients with advanced breast cancer that is ER+ and HER2-. Imlunestrant works by blocking estrogen receptors on cancer cells, while abemaciclib stops the cells from multiplying. The goal is to see if these treatments work better than standard hormone therapy.
Recruiting2 awards Phase 39 criteria
More about Peter A. Kaufman
Clinical Trial Related1 year of experience running clinical trials · Led 8 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Peter A. Kaufman has experience with
- Abemaciclib
- Fulvestrant
- Imlunestrant
- Exemestane
- LY3484356
- Zanidatamab
Breakdown of trials Peter A. Kaufman has run
Breast Cancer
Cancer
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter A. Kaufman specialize in?
Peter A. Kaufman focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved Stage IV patients, or patients who are ER positive.
Is Peter A. Kaufman currently recruiting for clinical trials?
Yes, Peter A. Kaufman is currently recruiting for 3 clinical trials in Burlington Vermont. If you're interested in participating, you should apply.
Are there any treatments that Peter A. Kaufman has studied deeply?
Yes, Peter A. Kaufman has studied treatments such as Abemaciclib, Fulvestrant, Imlunestrant.
What is the best way to schedule an appointment with Peter A. Kaufman?
Apply for one of the trials that Peter A. Kaufman is conducting.
What is the office address of Peter A. Kaufman?
The office of Peter A. Kaufman is located at: The University of Vermont Medical Center Inc., Burlington, Vermont 05401 United States. This is the address for their practice at the The University of Vermont Medical Center Inc..
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.